

BILL SUMMARY
1st Session of the 59th Legislature

Bill No.:	SB513
Version:	FA1
Request Number:	8181
Author:	Rep. Miller
Date:	4/20/2023
Impact:	See Below

Research Analysis

The floor substitute for SB 513 requires that each health benefit plan provide coverage for biomarker testing and documented evidence of such coverage including:

- Labeled indications for tests that are approved or cleared by the United States Food and Drug Administration (FDA).
- Tests for a drug that is approved by the FDA.
- Precautions on FDA approved drug labels.
- National coverage determinations or Medicare administrative contractor local coverage determinations.
- Nationally recognized clinical practice guidelines and consensus statements.

The measure also requires that the insured have access to a clear, readily available, and convenient process to request an exception to a coverage policy of a health benefit plan.

CHANGES IN FLOOR SUB VERSION FROM ENGROSSED:

The floor substitute for SB 513 defines the term "clinical utility" and adds language to state that biomarker testing provides clinical utility as demonstrated by medical and scientific evidence.

Prepared By: Matthew Brenchley

Fiscal Analysis

In its current form, SB513 requires that health benefit plans provide coverage for biomarker testing and documented evidence of such coverage. Officials from the Office of Management and Enterprise Services estimate that the annual impact of this change is less than \$500,000, or a 0.05% increase in total premium.

The floor amendment should not change the impact of the bill.

Prepared By: Zachary Penrod, House Fiscal Staff

Other Considerations

None.

